STERIS (STE) legal chief sells 1,419 shares, retains 35,259

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

STERIS plc senior vice president, general counsel and secretary John Adam Zangerle reported an open-market sale of 1,419 Ordinary Shares at $209.28 per share. After this transaction, he directly holds 35,259 Ordinary Shares.

As of June 15, 2026, 8,239 of these Ordinary Shares are restricted, with restrictions scheduled to lapse in stages between June 2, 2027 and June 4, 2029.

Insider Trade Summary 10b5-1

Net Seller: 1,419 shares ($296,968)

Net Sell 1 txn

Insider Zangerle John Adam

Role Sr. VP, Gen Counsel, and Sec.

Sold 1,419 shs ($297K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,419	$209.28	$297K

Holdings After Transaction: Ordinary Shares — 35,259 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 1,419 shares Sale price: $209.28 per share Shares held after: 35,259 shares +3 more

6 metrics

Shares sold 1,419 shares Ordinary Shares sold in open-market transaction

Sale price $209.28 per share Price for the 1,419 Ordinary Shares sold

Shares held after 35,259 shares Direct Ordinary Share holdings after the sale

Restricted shares 8,239 shares Restricted Ordinary Shares as of June 15, 2026

Restrictions lapse 2027-06-02 1,453 shares First tranche of restricted shares vesting

Restrictions lapse 2029-06-04 1,453 shares Final tranche of restricted shares vesting

Key Terms

Ordinary Shares, open-market sale, restricted, Sr. VP, Gen Counsel, and Sec.

4 terms

Ordinary Shares financial

"1,419 Ordinary Shares at $209.28 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted financial

"8,239 of these ordinary shares are restricted"

Sr. VP, Gen Counsel, and Sec. financial

"officer_title: "Sr. VP, Gen Counsel, and Sec.""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/16/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zangerle John Adam

(Last)

(First)

(Middle)

70 SIR JOHN ROGERSON'S QUAY

(Street)

DUBLIN 2

D02 R296

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Sr. VP, Gen Counsel, and Sec.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	06/15/2026		S		1,419	D	$209.28	35,259⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. As of June 15, 2026, 8,239 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,453 on June 2, 2027; 1,252 on June 3, 2027; 1,376 on June 4, 2027; 1,453 on June 2, 2028; 1,252 on June 5, 2028 and 1,453 on June 4, 2029.

Remarks:

	/s/ John P. Ubbing, Authorized Representative under Power of Attorney	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did STERIS (STE) report for John Adam Zangerle?

STERIS reported that John Adam Zangerle executed an open-market sale of 1,419 Ordinary Shares at $209.28 per share. The transaction involved non-derivative shares and was classified as a sale in the open market or a private transaction.

How many STERIS (STE) shares does John Adam Zangerle hold after the sale?

Following the reported sale, John Adam Zangerle directly holds 35,259 STERIS Ordinary Shares. This figure reflects his position after disposing of 1,419 shares in the open market at a reported price of $209.28 per share.

At what price were the STERIS (STE) shares sold in this Form 4 filing?

The 1,419 STERIS Ordinary Shares were sold at a price of $209.28 per share. This price applies to the entire reported transaction, which is characterized as a non-derivative, open-market or private sale by the reporting officer.

How many of John Adam Zangerle’s STERIS (STE) shares are restricted?

As of June 15, 2026, 8,239 of John Adam Zangerle’s STERIS Ordinary Shares are restricted. The filing notes that these restrictions will lapse in several tranches between June 2, 2027 and June 4, 2029, according to a preset schedule.

What is John Adam Zangerle’s role at STERIS (STE) in this Form 4?

In this Form 4, John Adam Zangerle is identified as an officer of STERIS, serving as senior vice president, general counsel, and secretary. The reported open-market sale reflects a transaction in his directly held Ordinary Shares of the company.

Are there any derivatives or options reported in this STERIS (STE) insider filing?

The insider filing shows only a non-derivative transaction in Ordinary Shares and lists no derivative positions. The derivative summary is empty, indicating no options, warrants, or other derivative securities are reported in connection with this particular Form 4.